Balyasny Asset Management
NBSE

Balyasny Asset Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Balyasny Asset Management’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-61
Closed -$5K – 2236
2018
Q1 		$5K Buy
+61
New +$9.07K ﹤0.01% 1885
2016
Q1 		– Sell
-70
Closed -$172K – 1576
2015
Q4 		$172K Buy
70
+10
+17% +$15.4K ﹤0.01% 1111
2015
Q3 		$66K Buy
60
+11
+22% +$12.7K ﹤0.01% 1081
2015
Q2 		$49K Buy
+49
New +$52.8K ﹤0.01% 1103

Other funds holding NBSE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Balyasny Asset Management's NBSE Position: Q2 2018 in Review

Balyasny Asset Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2018, closing a stake of 61 shares — an estimated $5K sold.

Balyasny Asset Management first reported a position in NBSE in Q2 2015 and held it in 4 quarters. The position peaked at $172K in Q4 2015. 33 funds tracked by Wall St. Rank hold NBSE as of Q2 2018.

  • Balyasny Asset Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 61 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $5K.
  • Balyasny Asset Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2015 and held it in 4 quarters.
  • Balyasny Asset Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $172K in Q4 2015.
  • 33 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Balyasny Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.